Sven Kili

Sven Kili

Presidente presso Sven Kili Consulting Ltd.

57 anni
Health Technology
Consumer Services
Finance

Profilo

Sven is an advisor to Saisei Ventures, participating in the investment process as a contributor to the investment advisory committee.
He was previously the CEO of Antion S.A., A Swiss-based allogeneic CAR-T biotech company and Head of Development for the CGT division of GSK Rare Diseases where he led teams developing and commercialising gene therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo gene therapy to be approved for children with ADA-SCID; Wiskott - Aldrich syndrome (WAS); Metachromatic Leukodystrophy (MLD) and Beta- Thalassemia and others.
Prior to this, he was Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery where he led the clinical development, approval and commercialisation activities of the first combined ATMP product in the EU for MACI®.
He and his team also prepared and submitted various Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US.
Before joining Genzyme, Sven led the cell therapy activities and oversaw all UK & Irish regulatory functions and was the QPPV for pharmacovigilance for the Geistlich Pharma.
Sven trained as an Orthopaedic surgeon in the UK and South Africa and since leaving full-time clinical practise has developed expertise Cell and Gene Therapy strategic company formation, clinical development, regulatory compliance, value creation, risk management and product safety, product launches and post-marketing activities.

Posizioni attive di Sven Kili

SocietàPosizioneInizio
Sven Kili Consulting Ltd. Presidente -
Direttore/Membro del Consiglio 01/01/2017
Standards Coordinating Body Direttore/Membro del Consiglio -
Consulente / Consigliere 01/09/2023
Tutte le posizioni attive di Sven Kili

Precedenti posizioni note di Sven Kili

SocietàPosizioneFine
XINTELA AB Direttore Tecnico/Scientifico/R&S 01/05/2022
Consulente / Consigliere 30/05/2018
Amministratore Delegato -
Corporate Officer/Principal -
Direttore Tecnico/Scientifico/R&S -
Vedi nel dettaglio l'esperienza di Sven Kili

Formazione di Sven Kili

The Royal College of Surgeons of England Doctorate Degree
University of Stellenbosch Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Sven Kili

Relazioni

33

Relazioni di 1° grado

11

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa1
XINTELA AB

Health Technology

Aziende private8

Health Technology

Sven Kili Consulting Ltd.

Health Technology

Health Technology

Standards Coordinating Body

Health Technology

Finance

Health Services

Vedi le connessioni aziendali